ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth
ViaDerma, Inc. (OTC Pink: VDRM) reported strong financial results for Q2 2024, achieving positive net income and significant cash flow growth. Key highlights include:
- Steady revenues of $300,191 for H1 2024
- Net income of $54,008 for the six-month period, a 171.5% increase from the previous year
- Cash reserves surged to $826,175, a 7,972% increase from year-end 2023
- Total liabilities reduced by 5.3% to $1,096,509
The company's lead product, Vitastem, an FDA-registered topical antibiotic, continues to gain market traction. ViaDerma is advancing its product pipeline in anti-aging skincare, pain management, and other areas. The company is also adopting a wholesale distribution model and exploring joint ventures to expand its market presence.
ViaDerma, Inc. (OTC Pink: VDRM) ha riportato risultati finanziari solidi per il secondo trimestre del 2024, registrando un reddito netto positivo e una crescita significativa del flusso di cassa. I punti salienti includono:
- Entrate stabili di $300,191 per il primo semestre del 2024
- Reddito netto di $54,008 per il periodo sei mesi, con un aumento del 171,5% rispetto all'anno precedente
- Riserve di cassa aumentate a $826,175, un incremento del 7,972% rispetto alla fine del 2023
- Passività totali ridotte del 5,3% a $1,096,509
Il prodotto di punta dell'azienda, Vitastem, un antibiotico topico registrato dalla FDA, continua a guadagnare terreno sul mercato. ViaDerma sta avanzando nel suo portafoglio prodotti in aree come la cura della pelle anti-invecchiamento, la gestione del dolore e altri settori. L'azienda sta anche adottando un modello di distribuzione all'ingrosso ed esplorando joint venture per espandere la sua presenza sul mercato.
ViaDerma, Inc. (OTC Pink: VDRM) reportó resultados financieros sólidos para el segundo trimestre de 2024, logrando un ingreso neto positivo y un crecimiento significativo en el flujo de caja. Los puntos clave incluyen:
- Ingresos estables de $300,191 para el primer semestre de 2024
- Ingreso neto de $54,008 para el período de seis meses, un aumento del 171.5% en comparación con el año anterior
- Reservas de efectivo aumentadas a $826,175, un incremento del 7,972% desde finales de 2023
- Pasivos totales reducidos en un 5.3% a $1,096,509
El producto principal de la empresa, Vitastem, un antibiótico tópico registrado en la FDA, sigue ganando tracción en el mercado. ViaDerma está avanzando en su línea de productos en el cuidado de la piel antienvejecimiento, el manejo del dolor y otras áreas. La empresa también está adoptando un modelo de distribución mayorista y explorando asociaciones para expandir su presencia en el mercado.
ViaDerma, Inc. (OTC Pink: VDRM)는 2024년 2분기 강력한 재무 결과를 보고하며, 긍정적인 순이익과 상당한 현금 흐름 성장을 달성했습니다. 주요 하이라이트는 다음과 같습니다:
- 2024년 상반기 동안 안정적인 수익 $300,191
- 6개월 동안의 순이익 $54,008으로, 지난해 대비 171.5% 증가
- 현금 보유고가 $826,175로, 2023년 연말 대비 7,972% 증가
- 총 부채가 5.3% 감소하여 $1,096,509
회사의 주력 제품인 Vitastem, FDA 등록 국소 항생제,가 계속해서 시장에서 주목받고 있습니다. ViaDerma는 항노화 피부 관리, 통증 관리 및 기타 분야에서 제품 파이프라인을 발전시키고 있습니다. 회사는 도매 유통 모델을 채택하고, 시장 진출을 확대하기 위해 공동 벤처를 탐색하고 있습니다.
ViaDerma, Inc. (OTC Pink: VDRM) a rapporté de solides résultats financiers pour le deuxième trimestre 2024, atteignant un revenu net positif et une croissance significative du flux de trésorerie. Les points saillants comprennent :
- Revenus stables de $300,191 pour le premier semestre 2024
- Revenu net de $54,008 pour la période de six mois, soit une augmentation de 171,5 % par rapport à l'année précédente
- Réserves de trésorerie ayant atteint $826,175, soit une augmentation de 7,972 % par rapport à la fin de 2023
- Passifs totaux réduits de 5,3 % à $1,096,509
Le produit phare de l'entreprise, Vitastem, un antibiotique topique enregistré auprès de la FDA, continue de gagner du terrain sur le marché. ViaDerma avance dans son pipeline de produits dans les soins anti-âge, la gestion de la douleur et d'autres domaines. L'entreprise adopte également un modèle de distribution en gros et explore des coentreprises pour élargir sa présence sur le marché.
ViaDerma, Inc. (OTC Pink: VDRM) hat starke finanzielle Ergebnisse für das zweite Quartal 2024 gemeldet und ein positives Nettoergebnis sowie ein signifikantes Wachstum des Cashflows erzielt. Die wichtigsten Highlights umfassen:
- Stabile Einnahmen von $300,191 für das erste Halbjahr 2024
- Nettoergebnis von $54,008 für den sechsmonatigen Zeitraum, ein Anstieg von 171,5% im Vergleich zum Vorjahr
- Cash-Reserven sind auf $826,175 angewachsen, was einem Anstieg von 7,972% gegenüber Ende 2023 entspricht
- Gesamtschulden verringert um 5,3% auf $1,096,509
Das Hauptprodukt des Unternehmens, Vitastem, ein von der FDA registriertes topisches Antibiotikum, gewinnt weiterhin an Marktanteilen. ViaDerma treibt seine Produktpipeline in den Bereichen Anti-Aging-Hautpflege, Schmerzmanagement und anderen Bereichen voran. Das Unternehmen übernimmt auch ein Großhandelsvertriebsmodell und untersucht Joint Ventures, um seine Marktpräsenz auszubauen.
- Achieved positive net income of $54,008 for H1 2024, a 171.5% increase from previous year's loss
- Cash reserves increased by 7,972% to $826,175
- Total liabilities reduced by 5.3% to $1,096,509
- Secured sale of 1 million units of tetracycline-based topical antibiotic to Nigeria
- Expanding product pipeline in various healthcare segments
- Slight decrease in revenue from $300,230 in H1 2023 to $300,191 in H1 2024
LOS ANGELES, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, announced its financial results for the second quarter and six-month period ending June 30, 2024. The company delivered a strong financial performance with notable revenue consistency, positive net income, and a robust increase in cash reserves.
Financial Highlights for Q2 2024:
- Revenue: ViaDerma maintained steady revenues of
$300,191 for the first half of 2024, compared to$300,230 for the same period in 2023, showing resilience in its sales despite challenging market conditions. - Net Income: The company achieved a net income of
$54,008 for the six-month period, a significant improvement from the net loss of$75,576 reported during the same period in 2023. This turnaround reflects a positive shift in profitability, representing a171.5% increase in earnings. - Cash Reserves: Cash and cash equivalents surged to
$826,175 as of June 30, 2024, a remarkable 7,972% increase compared to$10,243 at the end of 2023. This growth is attributed to enhanced cash flow from operations and improved financial management. - Liabilities: The company reduced its total liabilities to
$1,096,509 , compared to$1,157,684 at the end of 2023, reflecting a5.3% decrease in its debt burden.
The recent sale of 1 million units of its tetracycline-based topical antibiotic to Nigeria is not reflected in the financial results for Q2 2024. The first 500,000 units were shipped from the manufacturer in August 2024, with another 500,000 units scheduled for October 2024. The revenues from the August shipment will appear in the next quarterly report.
The report also highlighted ViaDerma's continued progress in its operations, particularly with its lead product, Vitastem, an FDA-registered topical antibiotic that has gained significant market traction. This product continues to be met with strong customer acceptance and positive clinical outcomes, contributing to the company’s steady revenue stream.
ViaDerma is advancing its product pipeline with innovations in anti-aging skincare, pain management, hair-loss treatments, sexual wellness products and a CBD-based product targeting inflammation and conditions like nicotine addiction, fibromyalgia, and multiple sclerosis. The company is also strengthening its market presence by adopting a wholesale distribution model to boost sales and expand product availability in new regions, and exploring joint ventures with established pharmaceutical companies.
“We're pleased with our strong Q2 results, which we believe marks the beginning of what we expect will lead to significantly higher growth for our Company,” said Dr. Christopher Otiko, President and CEO of ViaDerma.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC Pink: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative transdermal drug delivery technology solutions to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit: https://viaderma.com
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
Contact information:
Investor Relations
Email: ir@viaderma.com
Phone: 310-734-6111
FAQ
What were ViaDerma's (VDRM) key financial results for Q2 2024?
How did ViaDerma's (VDRM) revenue perform in Q2 2024?
What major sale did ViaDerma (VDRM) secure in 2024?
What is ViaDerma's (VDRM) strategy for market expansion?
